Gemcitabina_[Inn-Spanish]

Category

Gemcitabina_[Inn-Spanish]




Useful info

Gemcitabina_[Inn-Spanish] Brand names, Gemcitabina_[Inn-Spanish] Analogs

Gemcitabina_[Inn-Spanish] Brand Names Mixture

  • No information avaliable

    • Gemcitabina_[Inn-Spanish] Chemical_Formula

    C9H11F2N3O4

    Gemcitabina_[Inn-Spanish] RX_link

    http://www.rxlist.com/cgi/generic/gemcitab.htm

    Gemcitabina_[Inn-Spanish] fda sheet

    Gemcitabina_[Inn-Spanish] FDA

    Gemcitabina_[Inn-Spanish] msds (material safety sheet)

    Gemcitabina_[Inn-Spanish] MSDS

    Gemcitabina_[Inn-Spanish] Synthesis Reference

    No information avaliable

    Gemcitabina_[Inn-Spanish] Molecular Weight

    263.198 g/mol

    Gemcitabina_[Inn-Spanish] Melting Point

    168.64oC

    Gemcitabina_[Inn-Spanish] H2O Solubility

    Soluble

    Gemcitabina_[Inn-Spanish] State

    Solid

    Gemcitabina_[Inn-Spanish] LogP

    -1.318

    Gemcitabina_[Inn-Spanish] Dosage Forms

    Lyophilized powder for injection

    Gemcitabina_[Inn-Spanish] Indication

    For the first-line treatment of patients with metastatic breast cancer, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer and as first-line treatment for patients with adenocarcinoma of the pancreas.

    Gemcitabina_[Inn-Spanish] Pharmacology

    Gemcitabine is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (or DNA synthesis phase of the cell cycle), stopping normal development and division. Gemcitabine blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Gemcitabine blocks the incorporation of the thymidine nucleotide into the DNA strand.

    Gemcitabina_[Inn-Spanish] Absorption

    100%

    Gemcitabina_[Inn-Spanish] Toxicity

    Myelosuppression, paresthesias, and severe rash were the principal toxicities, LD50=500 mg/kg (orally in mice and rats)

    Gemcitabina_[Inn-Spanish] Patient Information

    General ¡ª Patients receiving therapy with Gemzar should be monitored closely by a physician
    experienced in the use of cancer chemotherapeutic agents. Most adverse events are reversible and
    do not need to result in discontinuation, although doses may need to be withheld or reduced.
    There was a greater tendency in women, especially older women, not to proceed to the next
    cycle.

    Laboratory Tests ¡ª Patients receiving Gemzar should be monitored prior to each dose with a
    complete blood count (CBC), including differential and platelet count. Suspension or
    modification of therapy should be considered when marrow suppression is detected.

    Gemcitabina_[Inn-Spanish] Organisms Affected

    Humans and other mammals